Pharmacokinetics and Retinal Toxicity of Various Doses of Intravitreal Triamcinolone Acetonide in Rabbits

Overview

Journal Mol Vis

Specialties Cell Biology
Molecular Biology
Ophthalmology

Date 2014 May 29

PMID 24868137

Citations 8

Authors

You-Fan Ye

Yong-Feng Gao

Hua-Tao Xie

Hai-Jun Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide (TA) in rabbits.

Methods: The rabbits received intravitreal injections of 4 mg and 8 mg TA. The drug concentrations were determined with high-performance liquid chromatography after extraction from the vitreous at various time points. The main pharmacokinetics parameters were calculated with 3p97 pharmacokinetics software. The intraocular pressure, electroretinography, and pathological examinations were evaluated before and after intravitreal injection of different doses of TA.

Results: The half-life of intravitreal injection of 4 mg and 8 mg TA was 24 days and 34 days, respectively. No significant differences were found in intraocular pressure (p>0.05) and the electroretinography b-wave amplitudes (p>0.05) among the rabbits before and after intravitreal injection of 4 mg and 8 mg TA. Light and electron microscopy did not show any retinal damage in any group.

Conclusions: Intravitreal injection of 4 mg and 8 mg TA are safe for the rabbit retina. The injection of 8 mg TA produced a longer vitreous half-life and had a prolonged effect on the retina. This conclusion may be referenced in the clinical application of TA in retinal diseases.

Citing Articles

In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits.

Alshaikh R, El Din R, Zaki R, Waeber C, Ryan K Mol Pharm. 2024; 21(7):3310-3320.

PMID: 38856116 PMC: 11220753. DOI: 10.1021/acs.molpharmaceut.4c00063.

In Situ Formation of Injectable Gelatin Methacryloyl (GelMA) Hydrogels for Effective Intraocular Delivery of Triamcinolone Acetonide.

Shen C, Zhao X, Ren Z, Yang B, Wang X, Hu A Int J Mol Sci. 2023; 24(5).

PMID: 36902389 PMC: 10003315. DOI: 10.3390/ijms24054957.

Internal limiting membrane peeling in macular hole surgery.

Pradhan D, Agarwal L, Joshi I, Kushwaha A, Aditya K, Kumari A Ger Med Sci. 2022; 20:Doc07.

PMID: 35813123 PMC: 9204259. DOI: 10.3205/000309.

Comparative study on pharmacokinetics and toxicity of intravitreal and sub-Tenon injection of triamcinolone acetonide in ocular tissues.

Arie Y, Miyai H, Suzuki A, Okabe T, Takashima M, Takata M Int J Ophthalmol. 2020; 13(12):1864-1871.

PMID: 33344183 PMC: 7708352. DOI: 10.18240/ijo.2020.12.04.

Effect of fluocinolone acetonide 0.2 μg/day implant on the decision to drive in patients with diabetic macular oedema: a report from the FAME study.

Grewal D, Fletcher D, Hariprasad S, Suner I BMJ Open Ophthalmol. 2020; 4(1):e000405.

PMID: 31909197 PMC: 6936565. DOI: 10.1136/bmjophth-2019-000405.

References

Spandau U, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas J . Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005; 89(8):999-1003. PMC: 1772791. DOI: 10.1136/bjo.2004.062596. View

Kwon S, Kim Y, Bang Y, Lee J, Park I . Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion. J Ocul Pharmacol Ther. 2012; 29(1):5-9. DOI: 10.1089/jop.2011.0249. View

Pearson P, Jaffe G, Martin D, Cordahi G, Grossniklaus H, Schmeisser E . Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol. 1996; 114(3):311-7. DOI: 10.1001/archopht.1996.01100130307014. View

Li Y, Chen H, Hou J, Zhang Y, Li G, Gu X . Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide. Retina. 2011; 32(2):364-74. DOI: 10.1097/IAE.0b013e31821e1f7c. View

Kim H, Csaky K, Gravlin L, Yuan P, Lutz R, Bungay P . Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006; 26(5):523-30. DOI: 10.1097/00006982-200605000-00005. View

Macky T, Helmy D, El Shazly N . Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol. 2006; 245(6):817-24. DOI: 10.1007/s00417-006-0459-3. View

Morrison V, Koh H, Cheng L, Bessho K, Davidson M, Freeman W . Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina. 2006; 26(3):339-44. DOI: 10.1097/00006982-200603000-00014. View

Jonas J . Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004; 137(3):560-2. DOI: 10.1016/j.ajo.2003.08.012. View

Kamppeter B, Cej A, Jonas J . Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology. 2008; 115(8):1372-5. DOI: 10.1016/j.ophtha.2008.01.019. View

10.

Tammewar A, Cheng L, Kayikcioglu O, Falkenstein I, Kozak I, Goldbaum M . Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections. Br J Ophthalmol. 2008; 92(6):810-3. PMC: 2776725. DOI: 10.1136/bjo.2007.126227. View

11.

Yi N, Davis J, Salmon J, Gilger B . Ocular distribution and toxicity of intravitreal injection of triamcinolone acetonide in normal equine eyes. Vet Ophthalmol. 2008; 11 Suppl 1:15-9. DOI: 10.1111/j.1463-5224.2008.00636.x. View

12.

Yalcinbayir O, Gelisken O, Kaderli B, Avci R . Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema. Ophthalmologica. 2011; 225(4):222-7. DOI: 10.1159/000324714. View

13.

Feigenbaum A, KORNBLUTH W . Intravitreal injection of penicillin in a case of incipient abscess of the vitreous following extracapsular cataract extraction; perfect cure. Ophthalmologica. 2010; 110:300-5. DOI: 10.1159/000300284. View

14.

McCuen 2nd B, Bessler M, Tano Y, Chandler D, MACHEMER R . The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981; 91(6):785-8. DOI: 10.1016/0002-9394(81)90013-1. View

15.

Habot-Wilner Z, Sallam A, Pacheco P, Do H, McCluskey P, Lightman S . Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol. 2012; 21 Suppl 6:S56-61. DOI: 10.5301/EJO.2010.6062. View

16.

Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y . Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2005; 138(6):1046-8. DOI: 10.1016/j.ajo.2004.05.028. View

17.

Albini T, Abd-El-Barr M, Carvounis P, Iyer M, Lakhanpal R, Pennesi M . Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci. 2007; 48(1):390-5. DOI: 10.1167/iovs.06-0145. View

18.

Arikan G, Saatci A, Oner F . Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. Int J Ophthalmol. 2012; 4(4):402-5. PMC: 3340857. DOI: 10.3980/j.issn.2222-3959.2011.04.16. View

19.

Tano Y, Chandler D, MACHEMER R . Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980; 90(6):810-6. DOI: 10.1016/s0002-9394(14)75196-7. View

20.

Beer P, Bakri S, Singh R, Liu W, Peters 3rd G, Miller M . Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110(4):681-6. DOI: 10.1016/S0161-6420(02)01969-3. View